DHFR
Overview
DHFR (Dihydrofolate Reductase) encodes the enzyme that reduces dihydrofolate to tetrahydrofolate, an essential step in nucleotide biosynthesis. DHFR is the canonical target of antifolate anticancer agents such as methotrexate. Focal amplification of DHFR in bladder TCC has been identified as potentially therapeutically relevant given this established drug-target relationship.
Alterations observed in the corpus
- Focal amplification at 5q in 14/99 (14%) of bladder TCC tumors; flagged as therapeutically relevant given DHFR is the target of antifolate anticancer agents PMID:24121792
Cancer types (linked)
- BLCA: focal amplification in 14% of TCC; implicated as a therapeutic opportunity PMID:24121792
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data reported in the current corpus.
Therapeutic relevance
- DHFR is the established target of antifolate drugs (e.g., methotrexate, pemetrexed); 14% amplification rate in bladder TCC raises the possibility of DHFR-driven resistance or antifolate sensitivity in this subset PMID:24121792
Open questions
- Whether DHFR amplification confers sensitivity or resistance to antifolate agents in bladder TCC has not been functionally tested in the current corpus.
Sources
This page was processed by crosslinker on 2026-05-09.